No Data
INNOCARE (09969.HK) repurchased 0.1 million shares at a cost of 0.599 million Hong Kong dollars on December 27.
Gelonghui, December 27, INNOCARE (09969.HK) announced that on December 27, it spent 0.599 million HKD to repurchase 0.1 million shares.
Express News | Star market closing review: Most stocks in the Semiconductors Sector declined, while stocks in the Military Industry and Biological Product sectors were relatively active.
December 24 repurchase collection | TENCENT, HSBC Holdings and others have repurchased, with TENCENT spending 0.503 billion HKD.
According to a disclosure from HKEX on December 27, TENCENT (00700.HK), HSBC Holdings (00005.HK), and others repurchased shares. ① TENCENT (00700.HK) repurchased 1.2 million shares of common stock on December 24, involving an amount of 0.503 billion Hong Kong dollars, with a repurchase price ranging from 421.4 to 417.8 Hong Kong dollars per share. Since the buyback authorization resolution, the total number of repurchased securities is 0.226 billion shares, accounting for 2.395% of the number of issued shares at the time the ordinary resolution was passed. ② HSBC Holdings (00005.HK)
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
INNOCARE (09969.HK) spent 0.6315 million HKD to repurchase 0.106 million shares on December 24.
Glory Hong Kong reported on December 24 that INNOCARE (09969.HK) announced that on December 24, 2024, it spent 0.6315 million Hong Kong dollars to repurchase 0.106 million shares, with the repurchase price ranging from 5.86 to 6 Hong Kong dollars per share.
InnoCare Pharma Granted Waiver for Director Appointment
